Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

KM-819 for Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03022799
Recruitment Status : Unknown
Verified December 2016 by Kainos Medicine Inc..
Recruitment status was:  Recruiting
First Posted : January 18, 2017
Last Update Posted : January 18, 2017
Sponsor:
Information provided by (Responsible Party):
Kainos Medicine Inc.

Brief Summary:

This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) following the escalation of single and multiple doses of KM-819.

The study will consist of 2 parts. In Part A, up to 5 cohorts of young adult male subjects, and 1 single dose cohort of elderly male or post menopausal female subjects will receive escalating single doses of KM-819. The food effect will be investigated in one of the single dose cohorts of young adult male subjects, who will be crossed-over to the fed condition. Once the dose level is selected for the crossed-over to the fed condition and elderly subjects, the protocol will be amended to specify the dose level. In Part B, up to 4 cohorts of healthy young adult male subjects and 1 multiple dose cohort of elderly male or post menopausal female subjects will receive escalating multiple doses of KM-819. Part B will be conducted after completion of all cohorts of young adult male subjects in Part A.

Dose escalation to the next level will be determined using safety, tolerability, and PK data of the previous cohort.

Part A, Single Ascending Dose (SAD) Up to 40 healthy young adult male subjects and 8 healthy elderly male or post menopausal female subjects will be enrolled and randomized to receive either KM-819 or placebo.

Each of the 5 dose escalation cohorts consists of 8 healthy young adult male subjects; 6 subjects will receive 10, 30, 100, 200, or 400 mg of KM-819 and 2 subjects will receive placebo. In each single dose cohort, dosing of subjects will be sentinel, i.e., 2 subjects will be dosed on the first day (1 subject will receive active treatment and 1 subject will receive placebo) and the remaining 6 subjects will be dosed at least 24 hours after the first 2 subjects.

Cohorts will be dosed sequentially with escalating doses. One of the cohorts will be crossed-over to the fed condition to assess the effect of food as decided by Investigator and Sponsor during the study after completion of the 2nd dose cohort (30 mg).

Eight elderly male or post-menopausal female subjects will be enrolled into an additional cohort; 6 subjects will receive KM-819 at a dose level not exceeding the highest dose tested in the young adult male cohorts and 2 subjects will receive placebo.

Part A consists of a Screening period of up to 28 days, and a 3 day Confinement period when subjects are hospitalized for study activities. Subjects are required to return for outpatient visits on Day 4, 7 and for the Follow up Visit on Day 14. The cohort that crossed-over to the fed condition will undergo the same procedure up to the Outpatient Visit on Day 4. Subjects will be confined for 3 days for the second time, and are required to return for outpatient Visit 5 (Day 4), Visit 6 (Day 7), and for a Follow up Visit 7 (Day 14).

Part B, Multiple Ascending Dose (MAD) Up to 32 healthy young adult male subjects and 8 healthy elderly male or post menopausal female subjects will be enrolled and randomized to receive either KM-819 or placebo.

Each of the 4 dose escalation cohorts consists of 8 healthy young adult male subjects; 6 subjects will receive 30, 100, 200, or 400 mg of KM-819 once a day (QD) for 7 days and 2 subjects will receive placebo. Cohorts will be dosed sequentially with escalating doses.

Eight elderly male or post-menopausal female subjects will be enrolled into an additional cohort; 6 subjects will receive KM-819 at a dose level not exceeding the highest dose tested in the young adult male cohorts and 2 subjects will receive placebo.


Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: KM-819 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food Effect
Study Start Date : October 2016
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: KM-819
Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
Drug: KM-819
Placebo Comparator: Placebo
Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
Drug: Placebo



Primary Outcome Measures :
  1. Adverse Events [ Time Frame: throughout study completion, around 6 weeks ]

    All AEs will be coded using the latest available version 19.1 of the Medical Dictionary for Regulatory Activities (MedDRA).

    A treatment-emergent adverse event (TEAE) is defined as an AE that begins or that worsens in severity after at least one dose of the study drug has been administered.


  2. Concomitant Medication [ Time Frame: throughout study completion, around 6 weeks ]

    Concomitant medication will be coded using the World Health Organization-Drug Dictionary (WHO-DD) (Version WHO-DD March 2016) and will be classified by Anatomical Therapeutic Chemical (ATC) categories.

    Any medication that the subject takes other than the study drug, including herbal and other non-traditional remedies, is considered a concomitant medication. Prior concomitant medications are defined as those taken from Screening until the time of the first study drug administration. Concomitant medications are defined as those taken at the time of or after the first study drug administration.



Secondary Outcome Measures :
  1. Cmax (Maximum plasma concentration determined directly from the concentration-time profile) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  2. tmax (Time to achieve maximum observed plasma concentration determined directly from the concentration-time profile) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  3. t½ (Apparent terminal elimination half life) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  4. Tlag (Lag time) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  5. λz (Terminal elimination rate constant) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  6. AUClast (Area under the plasma concentration-time from predose (time 0) to the last quantifiable concentration) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  7. AUCinf (Area under the plasma concentration-time curve from predose (time 0) extrapolated to infinity) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  8. %AUCex (Percentage of AUCinf that is due to extrapolation beyond tlast) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  9. CL/F (Apparent oral clearance) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  10. Vz/F (Apparent volume of distribution) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  11. AUCINF_D_obs (AUCinf divided by dose) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
  12. AUClast_D (AUClast divided by dose) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  13. Cmax_D (Maximum observed concentration divided by dose) [ Time Frame: Part A: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours postdose ]
    Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose

  14. Ctrough (Observed concentration before dosing) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  15. Cmaxs (Maximum plasma concentration determined directly from the concentration-time profile) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  16. Cmin (Minimum plasma concentration determined directly from the concentration-time profile) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  17. AUCtau (Area under the plasma concentration-time curve for a dosing interval) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  18. Rac(AUC) (Observed accumulation by AUC) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  19. Rac (Cmax) (Observed accumulation by Cmax) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  20. AUCtau_D (AUCtau divided by dose) [ Time Frame: Part B: Day 1 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose, predose on Days 2, 3, 4, 5, 6, and on Day 7 predose (within 30 minutes prior to study drug administration) and 0.25, 0.5, 1, ]
  21. qualitative analysis of KM-819 and possible metabolic profiling in Urine [ Time Frame: Part A: pre-dose and 0-24 hours post-dose ]
    Urine samples will be used for qualitative analysis of KM-819 and possible metabolic profiling.

  22. the concentration of KM-819 in CSF [ Time Frame: Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) ]
    For cerebrospinal fluid (CSF) PK, the concentration of KM-819 will be listed.

  23. Bond and Lader Visual Analogue Scale (VAS) [ Time Frame: Part A: Day -1, 1, 2, 3 and 4 / Part B: Day-1, 1, 2, 7, and 8 ]

    The Bond-Lader VAS will be analyzed using 3 factor scores: alertness, contentedness, and calmness. Calculation of these 3 scores is based on the main factors resulting from statistical factor analysis. A high score indicates impairment.

    1. Alertness (9 subscales): [Q1 + Q3 + (100 - Q4) + Q5 + (100 - Q6) + (100 - Q9) + Q11 + (100 - Q12) + Q15] / 9
    2. Contentedness (5 subscales): [Q7 + (100 - Q8) + Q13 + (100 - Q14) + (100 - Q16)] / 5
    3. Calmness (2 subscales): [Q2 + (100 - Q10)] / 2

  24. Profile of Mood States (POMS) [ Time Frame: Part A: Day -1, 1, 2, 3 and 4 / Part B: Day-1, 1, 2, 7, and 8 ]
    POMS will be used to describe subjects' feelings with a questionnaire containing 65 words/statements. Feelings will be scored using different statement: "Not at All", "A Little", "Moderately", "Quite a lot", and "Extremely".

  25. Korean Wechsler Adult Intelligence Scale-IV (K-WAIS-IV) [ Time Frame: Part A: Day -1, 1, 2, 3 and 4 / Part B: Day-1, 1, 2, 7, and 8 ]
    The K-WAIS-IV consists of an assessment of the cognitive ability using a core battery of 10 unique subtests (Block Design, Similarities, Digit Span, Matrix Reasoning, Vocabulary, Arithmetic, Symbol Search, Visual Puzzles, Information, and Coding) that focus on four specific domains of intelligence: verbal comprehension, perceptual reasoning, working memory, and processing speed. And only the Coding subtest will be assessed in this study.

  26. Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Part A: Screening and day 3 / Part B: Screening, day 3 and 8 ]
    The C-SSRS is a scale that captures the occurrence, severity and frequency of suicide-related thoughts and behaviors during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred.

  27. Alpha synuclein oligomer in plasma and CSF [ Time Frame: Plasma - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) / CSF - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) ]
  28. total Tau in plasma and CSF [ Time Frame: Plasma - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) / CSF - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) ]
  29. phospho-Tau in plasma and CSF [ Time Frame: Plasma - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) / CSF - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) ]
  30. ratio of CSF concentration/Plasma Cmax [ Time Frame: Plasma - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) / CSF - Part B: Day 1 (at -120 minutes to 0 minute prior to the first dosing) and on Day 7 (at 1 hour after last dosing) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent and privacy language as per national regulations must be obtained from the subject prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  2. Male subject should be 19 to 45 years old (for young adult cohorts) or over 60 years old (for elderly cohorts).
  3. Subject has a body mass index (BMI) range of 18.5 to 30 kg/m2 inclusive at Screening.
  4. Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continuing throughout the study period and for 90 days after final study drug administration. Highly effective contraception is defined as:

    • Established use of oral, injected, or implanted hormonal methods of contraception
    • Placement of an intrauterine device or intrauterine system
    • Barrier methods of contraception: condom with spermicidal foam, gel, film, cream, suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, or suppository
  5. Male subject must not donate sperm starting at Screening, throughout the study period and for at least 90 days after final study drug administration.
  6. Female subject must be over 60 years old and post-menopausal (defined as at least 1 year without any menses) prior to Screening.
  7. Subject agrees not to participate in another investigational study while on study treatment.

Exclusion Criteria:

  1. Subject has a known or suspected hypersensitivity to KM-819, or any components of the formulation(s) used.
  2. Subject has previously participated in a clinical study with KM-819.
  3. Subject has any of the liver enzymes (aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, γ glutamyl transferase) or total bilirubin (TBIL) above the upper limit of normal (ULN). If any liver enzyme is > 1 × ULN but < 1.5 × ULN, the assessment may be repeated once during the Screening period or on check-in. If the repeated assessment is above the ULN, it is exclusionary. If the initial value is > 1.5 × ULN, it cannot be repeated and is exclusionary.
  4. Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, allergic rhinitis or rhino-conjunctivitis, or house dust mite allergy at time of dosing).
  5. Subject with a history of a suicide attempt or suicidal behavior. Any recent suicidal ideation (a level of 4 or 5) within the last 3 months, or having a positive C-SSRS at check-in (Day -1), or who is at significant risk to commit suicide, as judged by the Investigator using the C SSRS at Screening.
  6. Subject has/had febrile illness or symptomatic viral, bacterial (including upper respiratory infection) or fungal (non-cutaneous) infection within 1 week before site check-in.
  7. Subject has any clinically significant abnormality following the Investigator's review of the physical examination, ECG, and protocol-defined clinical laboratory tests at Screening or site check-in.
  8. Subject has a mean pulse < 40 or > 90 beats per minute (bpm); mean systolic blood pressure (SBP) > 140 mmHg; or mean diastolic blood pressure (DBP) > 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for 5 minutes; pulse will be measured automatically) at Screening or check-in. If the mean pulse, mean SBP, or mean DBP is out of the range specified above, 1 additional triplicate measurement may be taken at Screening and check-in.
  9. Subject has a mean QT interval corrected for heart rate according to Fridericia (QTcF) interval of > 430 msec (for males) and > 450 msec (for females) at Screening or check-in. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken. If this triplicate also gives an abnormal result, the subject should be excluded.
  10. Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease, or a family history of Long QT Syndrome.
  11. Subject has use of any prescribed or non-prescribed drugs (including vitamins, hormone replacement therapy, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks before study drug administration. Acetaminophen up to 2000 mg/day is allowed.
  12. Subject has had any use of tobacco- or nicotine-containing products within 6 months prior to Screening.
  13. Subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to Screening or has a history of alcoholism or abuse of amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates (drugs-of-abuse) within the past 2 years prior to Screening (Note: 1 unit = 355 mL of beer, 118 mL of wine, or 29 mL of spirits/hard liquor) or the subject tests positive at Screening or site admission for alcohol or drugs of-abuse.
  14. Subject has used any drugs-of-abuse within 3 months before check in.
  15. Subject has used any inducers of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to check-in.
  16. Subject has any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood, or blood products within 60 days or donated plasma within 7 days before check-in.
  17. Subject has a positive serology test for hepatitis B surface antigen (HbsAg), anti hepatitis A virus Immunoglobulin M (HAV IgM), anti-hepatitis C virus (HCV Ab), or anti-human immunodeficiency virus (HIV Ab).
  18. Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 3 months or 5 half lives, whichever is longer, before the initiation of Screening.
  19. Subject has (recent history of) any other condition which, in the opinion of the Investigator, precludes the subject's participation in the trial.
  20. Subject is an employee of the Kainos Medicine, Inc. or vendors involved in the study.

    Additional Exclusion Criteria for Young Adult Subjects

  21. For young adult cohorts, subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy, as judged by the Investigator or designee.

Exclusion Criteria for Elderly Subjects Replacement for Exclusion No. 8 above 8. Subject has a mean pulse < 50 or > 90 bpm; mean SBP > 160 mmHg; mean DBP > 100 mmHg (measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically).

Replacement for Exclusion No. 21 above 21. For elderly cohorts, subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy that is not well managed and stable, as judged by the Investigator or designee.

Additional Exclusion Criteria 22. Elderly subject is excluded if the Glomerular Filtration Rate (calculated based on Cockcroft-Gault formula) is < 60 mL/min/1.73 m2.

23. Clinically significant abnormal findings in the lumbar X-ray examination (only for elder subjects for MAD study).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03022799


Contacts
Layout table for location contacts
Contact: Jae Moon Lee, PhD +82 2 567 7419 jlee@kainosmedicine.com
Contact: Yun Tae Chung, PhD +82 2 470 9601 ytchung54@kainosmedicine.com

Locations
Layout table for location information
Korea, Republic of
CHA Bundang Medical Center, CHA University Recruiting
Seongnam, Gyeonggi-do, Korea, Republic of, 13496
Contact: Kyoung Soo Lim, MD, PhD    +82 31 780 5324    kslim@cha.ac.kr   
Contact: Min-Kyoung Kim, MD    +82 31 780 5031    mkkim0212@chamc.co.kr   
Sponsors and Collaborators
Kainos Medicine Inc.
Investigators
Layout table for investigator information
Study Director: Jae Moon Lee, PhD Kainos Medicine Inc.

Layout table for additonal information
Responsible Party: Kainos Medicine Inc.
ClinicalTrials.gov Identifier: NCT03022799     History of Changes
Other Study ID Numbers: KMCP-819-K101
First Posted: January 18, 2017    Key Record Dates
Last Update Posted: January 18, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Individual identifiable personal information will not be shared. All individuals will be coded by a 4-digit study code.

Keywords provided by Kainos Medicine Inc.:
FAF1
Fas (TNFRSF6)-associated factor 1
FAF1 inhibitor
KM-819

Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases